Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sawai Maintains Strong Domestic Performance, Continues To Flounder In US

Firm Thrives In Japan As Competitors Struggle, But Suffers In US Due To Rival Launches

Executive Summary

Sawai’s Q2 results mirrored those of Q1, with a strong performance in Japan but a weak one in the US. The firm is continuing to focus on establishing new production facilities in both territories.

You may also be interested in...



Sawai’s Japan Core Profit Tumbles 39% As Upsher-Smith Continues Revival

Sawai’s Q1 momentum spread into its overall first half financial results, with setbacks and risks in its dominant Japanese business and greener shoots for its formerly spluttering Upsher-Smith operation in the US.

Keppra And Velcade Rivals Among Sawai’s New Listings

Rivals to Careram, Keppra, Patanol, Velcade and Volibris have been listed with Japan’s NHI drug price list by Sawai, as the company seeks to capitalize on its position as a leading supplier in the market.

Towa Raises Japanese Expectations Amid Uncertain Business Climate

Towa has issued a minor upward revision to its full-year guidance after its domestic business delivered higher than expected sales and profit growth during H1, but uncertainty in the Japanese generics market and concerns over the firm’s overseas units have led some analysts to raise questions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel